VIDEOS

Micardis Cardiovascular Protection  

01:13

Micardis Cardiovascular Protection
Micardis Efficacy vs ACE Inhibitors  

01:08

Micardis Efficacy vs ACE Inhibitors
Twynsta Efficacy and Coverage  

01:12

Twynsta Efficacy and Coverage
Guidelines Recommendation for Diabetic Hypertensive Patients  

01:06

Guidelines Recommendation for Diabetic Hypertensive Patients
Why Micardis?  

01:26

Why Micardis?
Actilyse Infusion Preparation  

03:16

Actilyse Infusion Preparation
Who can benefit from ICS  

02:02

Who can benefit from ICS
Superiority of LABA/LAMA over LABA/ICS  

02:02

Superiority of LABA/LAMA over LABA/ICS
Respimat for First Use - Teacher  

01:15

Respimat for First Use - Teacher
OTIVACTO animation storyboard  

02:37

OTIVACTO animation storyboard
Treatment Including Thrombolysis  

01:19

Treatment Including Thrombolysis
Stroke Causes and Diagnosis  

02:22

Stroke Causes and Diagnosis
Recognition of Stroke  

02:09

Recognition of Stroke
Metalyse Administration Video  

02:13

Metalyse Administration Video
What is the leading cause of death in patients with type 2 diabetes?  

01:32

What is the leading cause of death in patients with type 2 diabetes?
Effect On Honeycombing Efficacy  

02:44

Effect On Honeycombing Efficacy
Prof. Richeldi & Prof. Maher video transcript: Why watch & wait?  

01:50

Prof. Richeldi & Prof. Maher video transcript: Why watch & wait?
What are your thoughts on the 35% relative risk reduction?  

01:42

What are your thoughts on the 35% relative risk reduction?
Dosage & Administration  

01:18

Dosage & Administration
Efficacy with Concomitant Emphysema  

03:17

Efficacy with Concomitant Emphysema
Mechanism of Action  

03:20

Mechanism of Action
INPULSIS-ON Prof. Richeldi & Prof. Maher video: Early use of antifibrotics and the benefit to patients ?  

00:58

INPULSIS-ON Prof. Richeldi & Prof. Maher video: Early use of antifibrotics and the benefit to patients ?
Prof. Richeldi & Prof. Maher video transcript: Why watch & wait?  

01:50

Prof. Richeldi & Prof. Maher video transcript: Why watch & wait?
Prof. Richeldi & Prof. Maher Interpreting acute exacerbations data from INPULSIS-ON trial  

02:06

Prof. Richeldi & Prof. Maher Interpreting acute exacerbations data from INPULSIS-ON trial
Prof. Richeldi & Prof. Maher video: evaluating FVC data from INPULSIS-ON trial  

02:013

Prof. Richeldi & Prof. Maher video: evaluating FVC data from INPULSIS-ON trial
OFEV - INPULSIS ON: Mortality data (Dr Maher- Dr Richaldi)  

02:22

OFEV - INPULSIS ON: Mortality data (Dr Maher- Dr Richaldi)
OFEV - INPULSIS ON (Dr Maher- Dr Richaldi)  

02:16

OFEV - INPULSIS ON (Dr Maher- Dr Richaldi)
INPULSIS-ON Prof. Richeldi & Prof. Maher video & transcript: New guideline impact on the diagnosis of IPF  

01:06

INPULSIS-ON Prof. Richeldi & Prof. Maher video & transcript: New guideline impact on the diagnosis of IPF
Expert Opinion  

00:57

Expert Opinion
Survival Analysis  

05:58

Survival Analysis
Patients Subgroup Analysis  

09:33

Patients Subgroup Analysis
Lung Function at Baseline  

03:02

Lung Function at Baseline
Why was the data of the INPULSIS<sup>®</sup> and TOMORROW trials pooled?  

02:03

Why was the data of the INPULSIS® and TOMORROW trials pooled?
Is the glucose-lowering effect of Jardiance a barrier to cardiologists prescribing it?  

01:52

Is the glucose-lowering effect of Jardiance a barrier to cardiologists prescribing it?
What were the key findings from EMPA-REG OUTCOME?  

02:29

What were the key findings from EMPA-REG OUTCOME?
Should we move beyond glucose lowering as the main treatment goal?  

02:46

Should we move beyond glucose lowering as the main treatment goal?
What does lowering the risk of CV death? - John Wilding  

01:56

What does lowering the risk of CV death? - John Wilding
Are patients with type 2 diabetes at elevated CV risk?  

02:23

Are patients with type 2 diabetes at elevated CV risk?
Safety & Tolerability  

03:20

Safety & Tolerability
Early reduction in CV death with Jardiance  

01:01

Early reduction in CV death with Jardiance
Reduce the risk of mortality with Jardiance  

01:01

Reduce the risk of mortality with Jardiance
Reduce the risk of hospitalization for heart failure with Jardiance  

01:01

Reduce the risk of hospitalization for heart failure with Jardiance
EMPA-REG Outcome Results - Video  

02:30

EMPA-REG Outcome Results - Video
Patients could benefit from Jardiance across baseline HbA1c  

01:00

Patients could benefit from Jardiance across baseline HbA1c
Life happens: Car accidents  

00:32

Life happens: Car accidents
Life happens: How emergency situations affect life of patients on OAC treatment  

00:49

Life happens: How emergency situations affect life of patients on OAC treatment
Life happens: Appendicitis is one of the most frequent abdominal surgical emergencies  

00:42

Life happens: Appendicitis is one of the most frequent abdominal surgical emergencies
Idarucizumab (Praxbind®) patient case in gallbladder removal  

01:29

Idarucizumab (Praxbind®) patient case in gallbladder removal
RE-VERSE AD Study: Dr. Charles Pollack  

03:11

RE-VERSE AD Study: Dr. Charles Pollack
Idarucizumab (Praxbind®) real patient cases  

03:00

Idarucizumab (Praxbind®) real patient cases
Reversibility of NOAC therapies: the neurologist's perspective  

06:12

Reversibility of NOAC therapies: the neurologist's perspective
RE-DUAL PCI video  

02:14

RE-DUAL PCI video
About IPF - Intro  

00:51

About IPF - Intro
Dose Modification  

02:47

Dose Modification
About IPF - Tissue Repair  

01:41

About IPF - Tissue Repair
Reducing Acute Exacerbation  

01:06

Reducing Acute Exacerbation
Going beyond standard care of with Jardiance  

01:03

Going beyond standard care of with Jardiance
Dr. Pollack FAQ Praxbind - Thrombotic Signal  

01:40

Dr. Pollack FAQ Praxbind - Thrombotic Signal
Dr. Pollack FAQ Praxbind - The Meaning of Specific Reversal Agent  

01:55

Dr. Pollack FAQ Praxbind - The Meaning Of Specific Reversal Agent
Dr. Pollack FAQ Praxbind - Mortality Rate  

01:37

Dr. Pollack FAQ Praxbind - Mortality Rate
Dr. Pollack FAQ Praxbind - Difference of Time to Bleeding Cessation  

01:37

Dr. Pollack FAQ Praxbind - Difference of Time to Bleeding Cessation
Dr. Pollack FAQ Praxbind - 2nd Dose of Idarucizumab  

01:52

Dr. Pollack FAQ Praxbind - 2nd Dose of Idarucizumab
NOAC BID VS OD comparison  

01:17

NOAC BID VS OD comparison
MOA of Praxbind  

01:01

MOA of Praxbind
Reduce the risk of CV death with Jardiance-38 Percent  

01:01

Reduce the risk of CV death with Jardiance - 38%
RE-DUAL PCI Dr. Cannon  

11:40

RE-DUAL PCI Dr. Cannon
RE-DUAL PCI video  

02:14

RE-DUAL PCI video
Significanty lower major bleeding in Pradaxa dual therapy vs triple therapy after PCI with stenting  

03:52

Significanty Lower Major Bleeding In Pradaxa Dual Therapy Vs Triple Therapy After PCI With Stenting
Cardiovascular Pradaxa 2018 DoD RWE Video with Dr. Villines  

03:36

Cardiovascular Pradaxa 2018 DoD RWE Video With Dr. Villines
NOAC Safety in clinical practice vs RWE - Prof. G. Lip  

06:59

NOAC Safety in clinical practice vs RWE - Prof. G. Lip
Dr. Todd & Dr. Kenigsberg on RCT & RWE  

08:45

Dr. Todd & Dr. Kenigsberg on RCT & RWE
RE-DUAL Infographics Video  

02:28

RE-DUAL Infographics Video
Is Jardiance a medication for both endocrinologists and cardiologists?  

02:23

Is Jardiance a medication for both endocrinologists and cardiologists?
What are your views on the 38% relative risk reduction in CV death with Jardiance?  

02:22

What are your views on the 38% relative risk reduction in CV death with Jardiance?
What does lowering the risk of CV death? - Lars Ryden  

01:51

What does lowering the risk of CV death? - Lars Ryden
What are your thoughts on the 35% relative risk reduction?  

01:42

What are your thoughts on the 35% relative risk reduction?
Reduce the risk of CV death with Jardiance - 1/3  

01:01

Reduce the risk of CV death with Jardiance - 1/3
Long term benefit of Jardiance on life expectancy  

01:00

Long term benefit of Jardiance on life expectancy
Life happens: Car accidents  

00:32

Life happens: Car accidents
Life happens: How emergency situations affect life of patients on OAC treatment  

00:49

Life happens: How emergency situations affect life of patients on OAC treatment
Life happens: Appendicitis is one of the most frequent abdominal surgical emergencies  

00:42

Life happens: Appendicitis is one of the most frequent abdominal surgical emergencies
Idarucizumab (Praxbind®) patient case in gallbladder removal  

01:29

Idarucizumab (Praxbind®) patient case in gallbladder removal
RE-VERSE AD Study: Dr. Charles Pollack  

03:11

RE-VERSE AD Study: Dr. Charles Pollack
Idarucizumab (Praxbind®) real patient cases  

03:00

Idarucizumab (Praxbind®) real patient cases
Reversibility of NOAC therapies: the neurologist's perspective  

06:12

Reversibility of NOAC therapies: the neurologist's perspective
Dosage & Administration  

01:18

Dosage & Administration
Praxbind from a neurologist perspective  

06:19

Praxbind from a neurologist perspective
Real-life patient  

02:35

Real-Life Patient
Dr Tim Woods overview on reversibility  

04:19

Dr. Tim Woods Overview On Reversibility
RE-DUAL vs pioneer infographic_dose comparison

icoPDF

RE-DUAL Vs Pioneer Infographic Dose Comparison
RE-DUAL vs pioneer infographic_primary outcome measure comparison

icoPDF

RE-DUAL Vs Pioneer Infographic Primary Outcome Measure Comparison
Patient Gallbladder removal story  

01:32

Patient Gallbladder Removal Story
Patient Fall in Shower story  

01:30

Patient Fall In Shower story
Praxbind How to Use

01:33

Praxbind How to Use
Life Happens - Bike Accident

01:01

Life Happens - Bike Accident
LIFE CASE PRAXBIND  

02:58

LIFE CASE PRAXBIND
Life Happens - Emergency Surgery  

00:52

Life Happens - Emergency Surgery
Dr. Todd Villines overview on Pradaxa’s Safety  

09:06

Dr. Todd Villines overview on Pradaxa’s Safety
Dr. Kenigsberg overview on efficacy, safety & reversibility  

06:33

Dr. Kenigsberg overview on efficacy, safety & reversibility
Pradaxa Global Car Crash  

00:53

Pradaxa Global Car Crash
Changing clinical practice - The Re-Circuit Study by Dr Dhiraj Gupta video  

03:33

Changing clinical practice - The Re-Circuit Study by Dr Dhiraj Gupta video
Pradaxa Side by Side Video  

02:17

Pradaxa Side by Side Video
RE-DUAL PCI smart video (with subanalyses)  

03:14

RE-DUAL PCI smart video (with subanalyses)
Prof. Hugh Calkins Video  

07:09

Prof. Hugh Calkins Video
Pradaxa GLORIA-AF infographic animation (abbreviated version without RE-LY EU label analysis)  

02:56

Pradaxa GLORIA-AF Infographic Animation (Abbreviated Version Without RE-LY EU Label Analysis)
Pradaxa Story in Reverse Video  

01:18

Pradaxa Story in Reverse Video
Simplification of T2D therapy with Linagliptin (Trajenta®): 5mg once daily, the same dose regardless of renal function  

0:37

Simplification of T2D therapy with Linagliptin (Trajenta®): 5mg once daily, the same dose regardless of renal function
Linagliptin (Trajenta®): no extra monitoring of renal function for the sake of dose adjustment  

0:34

Linagliptin (Trajenta®): no extra monitoring of renal function for the sake of dose adjustment
Linagliptin (Trajenta®) has the benefits of the DPP4i class plus no dose reduction regardless of renal function  

0:41

Linagliptin (Trajenta®) has the benefits of the DPP4i class plus no dose reduction regardless of renal function
Complexity of T2D treatment accounts for not appropriately adjusting doses  

0:39

Complexity of T2D treatment accounts for not appropriately adjusting doses
CVOTs CARMELINA: What is the impact of the unique eGFR cut-off (>15) and high risk renal patients inclusion in the CARMELINA study?  

0:44

CVOTs CARMELINA: What is the impact of the unique eGFR cut-off (>15) and high risk renal patients inclusion in the CARMELINA study?
CVOTs CARMELINA: Prof. Ted Wu, the value of CARMELINA FOR T2D  

0:47

CVOTs CARMELINA: Prof. Ted Wu, the value of CARMELINA FOR T2D
Linagliptin (Trajenta®) benefits: proven efficacy, ease of use: one dose, regardless of renal function  

01:00

CVOTs CARMELINA: What is the impact of the eGFR cut-off of >15 in the CARMELINA trial?
CVOTs CARMELINA: Prof. M. Cooper on Clinical implication of CARMELINA  

00:46

CVOTs CARMELINA: Prof. M. Cooper on Clinical implication of CARMELINA
Linagliptin (Trajenta®): comparable efficacy within DPP4i and a simple way to keep patients on a licensed dose  

0:42

Linagliptin (Trajenta®): comparable efficacy within DPP4i and a simple way to keep patients on a licensed dose
Linagliptin (Trajenta®): proven HbA1c reduction with the same dose at any stage of renal function  

0:29

Linagliptin (Trajenta®): proven HbA1c reduction with the same dose at any stage of renal function
Linagliptin (Trajenta®) benefits: proven efficacy, ease of use: one dose, regardless of renal function  

0:44

Linagliptin (Trajenta®) benefits: proven efficacy, ease of use: one dose, regardless of renal function
Linagliptin (Trajenta®) has demonstrated high efficacy on a broad range of T2D populations regardless of renal function  

1:06

Linagliptin (Trajenta®) has demonstrated high efficacy on a broad range of T2D populations regardless of renal function
Linagliptin (Trajenta®) can be used even before renal function declines  

0:55

Linagliptin (Trajenta®) can be used even before renal function declines
DPP4i are similar in terms of HbA1c lowering  

0:18

DPP4i are similar in terms of HbA1c lowering
Higher efficacy in HbA1c patients  

0:45

Higher efficacy in HbA1c patients
Load more

Clinical studies

49.5 mmHg SBP reduction

icoPDF

49.5 mmHg SBP reduction
80 % goal achieved with Twynsta

icoPDF

80 % goal achieved with Twynsta
ONTARGET program: Study Design

icoPDF

ONTARGET program: Study Design
Telmisartan Attributes

icoPDF

Telmisartan Attributes
Telmisartan Therapeutic indications

icoPDF

Telmisartan Therapeutic indications
A classic ARB-HCTZ CHOICE for elderly patients

icoPDF

A classic ARB-HCTZ CHOICE for elderly patients
Early intervention FUE infographic

icoPDF

Early intervention FUE infographic
GOLD 2019

icoPDF

GOLD 2019
Addressing all COPD endpoints

icoPDF

Addressing all COPD endpoints
New Exacerbation data

icoPDF

New Exacerbation data
Otivacto real world evidence perspective

icoPDF

Otivacto real world evidence perspective
VIVACITO Infographic

icoPDF

VIVACITO Infographic
VESUTO Infographic

icoPDF

VESUTO Infographic
IRE Spiolto Tonado Trial Summary

icoPDF

IRE Spiolto Tonado Trial Summary
PHYSACTO Infographic

icoPDF

PHYSACTO Infographic
OTIVATO Infographic

icoPDF

OTIVATO Infographic
Energito Clinical Review

icoPDF

Energito Clinical Review
Thierry Troosters AJRCCM Articles in Press

icoPDF

Thierry Troosters AJRCCM Articles in Press
The Effect of Tiotropium.Olodaterol Versus Tiotropium

icoPDF

The Effect of Tiotropium.Olodaterol Versus Tiotropium
Masakazu Ichinose International Journal of COPD

icoPDF

Masakazu Ichinose International Journal of COPD
Kai-Michael Beeh Pulmonary Pharmacology & Therapeutics Kai-Michael Beeh Pulmonary

icoPDF

Kai-Michael Beeh Pulmonary Pharmacology & Therapeutics Kai-Michael Beeh Pulmonary
Francois Maltais Boehringer Ingelhiem

icoPDF

Francois Maltais Boehringer Ingelhiem
Fabienne Dobbels ORIGINAL ARTICLE REHABILITATION

icoPDF

Fabienne Dobbels ORIGINAL ARTICLE REHABILITATION
Recommended dose & administration method for Actilyse

icoPDF

Recommended dose & administration method for Actilyse
Actilyse Treatment Increases the Chance of a Favourable Outcome for Acute Stroke Patient

icoPDF

Actilyse Treatment Increases the Chance of a Favourable Outcome for Acute Stroke Patient
Post Call - Benefits of Earlier Treatment with Actilyse for Stroke Patient

icoPDF

Post Call - Benefits of Earlier Treatment with Actilyse for Stroke Patient
How should you perform the F.A.S.T. Test?

icoPDF

How should you perform the F.A.S.T. Test?
Dosing & Administering Metalyse

icoPDF

Dosing & Administering Metalyse
Management of acute MI

icoPDF

Management of acute MI
STEMI definition

icoPDF

STEMI definition
STEMI definition

icoPDF

STEMI treatment guidelines
Tenecteplase structure

icoPDF

STREAM TRIAL - Time is muscle!
Are patients with T2D at elevated CV risk?

icoPDF

Are patients with T2D at elevated CV risk?
EMPA-REG Outcome Results

icoPDF

EMPA-REG Outcome Results
EMPA-REG Outcome Study Design

icoPDF

EMPA-REG Outcome Study Design
RWE Larsen 2016

icoPDF

RWE Larsen 2016
RE-VERSE AD Study

icoPDF

RE-VERSE AD Study
Safety and Tolerability

icoPDF

Safety and Tolerability
Prescribing Information

icoPDF

Prescribing Information
RE-DUAL PCI

icoPDF

RE-DUAL PCI
2018 EHRA Guidelines on use of NOACs in Patients with AF

icoPDF

2018 EHRA Guidelines On Use of NOACs In Patients With AF
RE-DUAL PCI Cannon_NEJM_2017

icoPDF

RE-DUAL PCI Cannon NEJM 2017
RWE Hernandez_2017

icoPDF

RWE Hernandez 2017
Heidbuchel 2015 Europace (Updated European Heart Rhythm Association)

icoPDF

Heidbuchel 2015 Europace (Updated European Heart Rhythm Association)
2016 ESC Guidelines in AF

icoPDF

2016 ESC Guidelines in AF
Quick Guide of SPAF

icoPDF

Quick Guide of SPAF
RWE Bai_2017

icoPDF

RWE Bai 2017
RE-DUAL vs pioneer infographic_complete comparison

icoPDF

RE-DUAL vs pioneer infographic_complete comparison
Unmet Need Regional Data

icoPDF

Unmet Need Regional Data
Dosing

icoPDF

Dosing
INSTAGE Trial

icoPDF

INSTAGE Trial
Is it safe to use OFEV for more than 4 years?  

06:53

Is it safe to use OFEV for more than 4 years?
Combined evidence from the TOMORROW and INPULSIS<sup>®</sup> trials

icoPDF

Combined evidence from the TOMORROW and INPULSIS® trials
RWE comparison on safety & effectiveness of Pradaxa VS warfarin (Villines 2015)

icoPDF

RWE Comparison On Safety & Effectiveness Of Pradaxa VS Warfarin (Villines 2015)
RWE comparison on safety & effectiveness of Pradaxa VS warfarin (Larsen 2016 )

icoPDF

RWE Comparison On Safety & Effectiveness of Pradaxa VS Warfarin (Larsen 2016 )
RE-DUAL vs pioneer infographic_efficacy comparison

icoPDF

RE-DUAL Vs Pioneer Infographic Efficacy Comparison
How does Nintedanib benefit patients in preserving lung function?

icoPDF

How does Nintedanib benefit patients in preserving lung function?
Combined evidence from the TOMORROW and INPULSIS<sup>®</sup> trials

icoPDF

Combined evidence from the TOMORROW and INPULSIS® trials
How does dosing and administration of Nintedanib help compliance of IPF patients

icoPDF

How does dosing and administration of Nintedanib help compliance of IPF patients?
Adverse Event Management

icoPDF

Adverse Event Management
Long-term Safety and Tolerability of Nintedanib in Patients with IPF

icoPDF

Long-term Safety and Tolerability of Nintedanib in Patients with IPF
Consider Jardiance for T2D patients with heart failure

icoPDF

Consider Jardiance for T2D patients with heart failure
User Guide for Pradaxa

icoPDF

User Guide for Pradaxa
Praxbind User Guide

icoPDF

Praxbind User Guide
RE-DUAL PCI

icoPDF

RE-DUAL PCI
Is honeycombing in an HRCT, the sole detector of IPF?

icoPDF

Is honeycombing in an HRCT, the sole detector of IPF?
Medicare Graham_2015 RWE

icoPDF

Medicare Graham 2015 RWE
RWE Lin 2015

icoPDF

RWE Lin 2015
Lowest Renal Excretion Rate

icoPDF

Lowest Renal Excretion Rate
CVOTs CARMELINA: Time to first occurrence of adjudication-confirmed HHF

icoPDF

CVOTs CARMELINA: Time to first occurrence of adjudication-confirmed HHF
Patients Achieving HbA1c

icoPDF

Patients Achieving HbA1c
World Kidney Day 2019 TRAJENTA

icoPDF

World Kidney Day 2019 TRAJENTA
Hypo and Weight Gain

icoPDF

Hypo and Weight Gain
Graham 2019 Article in Press

icoPDF

Graham 2019 Article in Press
BMS/DES SUBGROUP of RE-DUAL PCI

icoPDF

BMS/DES SUBGROUP of RE-DUAL PCI
RE-DUAL THE RENAL FUNCTION SUBGROUP

icoPDF

RE-DUAL THE RENAL FUNCTION SUBGROUP
Patient Profile Synjardy

icoPDF

Patient Profile Synjardy
1 2 3 infographics

icoPDF

1 2 3 Infographics
SYNJARDY a twice daily oral medication that should be taken with meals

icoPDF

SYNJARDY a twice daily oral medication that should be taken with meals.
SYNJARDY helps you do more for patients like Abdullah by reducing their risk of CV death.

icoPDF

SYNJARDY helps you do more for patients like Abdullah by reducing their risk of CV death.
Diabetes magazine V1

icoPDF

Diabetes magazine V1
Load more